ATE390150T1 - Verwendungen einer targetierten therapeutischen formulierung fur die behandlung von altersbedingter makuladegeneration - Google Patents

Verwendungen einer targetierten therapeutischen formulierung fur die behandlung von altersbedingter makuladegeneration

Info

Publication number
ATE390150T1
ATE390150T1 AT05746977T AT05746977T ATE390150T1 AT E390150 T1 ATE390150 T1 AT E390150T1 AT 05746977 T AT05746977 T AT 05746977T AT 05746977 T AT05746977 T AT 05746977T AT E390150 T1 ATE390150 T1 AT E390150T1
Authority
AT
Austria
Prior art keywords
age
macular degeneration
related macular
pharmaceutical formulation
treatment
Prior art date
Application number
AT05746977T
Other languages
English (en)
Inventor
Robert F Hofmann
Original Assignee
Robert F Hofmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert F Hofmann filed Critical Robert F Hofmann
Application granted granted Critical
Publication of ATE390150T1 publication Critical patent/ATE390150T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT05746977T 2004-05-10 2005-05-10 Verwendungen einer targetierten therapeutischen formulierung fur die behandlung von altersbedingter makuladegeneration ATE390150T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56979204P 2004-05-10 2004-05-10

Publications (1)

Publication Number Publication Date
ATE390150T1 true ATE390150T1 (de) 2008-04-15

Family

ID=34980147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05746977T ATE390150T1 (de) 2004-05-10 2005-05-10 Verwendungen einer targetierten therapeutischen formulierung fur die behandlung von altersbedingter makuladegeneration

Country Status (7)

Country Link
US (1) US20050250756A1 (de)
EP (1) EP1747017B1 (de)
CN (1) CN101287496A (de)
AT (1) ATE390150T1 (de)
CA (1) CA2566190A1 (de)
DE (1) DE602005005666T2 (de)
WO (1) WO2005110484A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565363A1 (en) * 2004-05-06 2005-11-17 Robert F. Hofmann Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
US9301919B2 (en) * 2005-12-22 2016-04-05 Oakwood Laboratories, Llc Sublimable sustained release delivery system and method of making same
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
CN104546898A (zh) * 2013-10-28 2015-04-29 北京慧宝源企业管理有限公司 臭氧的离体治疗应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451480A (en) * 1982-04-16 1984-05-29 James Howard Brown Method of treating acne using ozonized materials
US4591602A (en) * 1982-04-16 1986-05-27 James H. Brown Ozonide esters and topical compositions containing same
US5126376A (en) * 1988-06-24 1992-06-30 Stephen Herman Method for treating viral infection using topical administration
US5086076A (en) * 1988-06-24 1992-02-04 Stephen Herman Antiviral pharmaceutical compositions comprising a terpene ozonide
US5190977A (en) * 1988-06-24 1993-03-02 Stephen Herman Antiviral compositions
US4983637A (en) * 1988-06-24 1991-01-08 Stephen Herman Method for treating viral infection of HIV
US5270344A (en) * 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
US5260342A (en) * 1988-06-24 1993-11-09 Stephen Herman Method for treating viral infection parenterally
US5364879A (en) * 1988-06-24 1994-11-15 Cliveden Ltd. Medical uses of trioxolane and diperoxide compounds
US5190979A (en) * 1988-06-24 1993-03-02 Stephen Herman Ozonides of terpenes and their medical uses
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
US6790463B2 (en) * 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
US6884797B2 (en) * 2001-03-30 2005-04-26 Robert F. Hofmann Targeted oxidative therapeutic formulation
CA2565363A1 (en) * 2004-05-06 2005-11-17 Robert F. Hofmann Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity

Also Published As

Publication number Publication date
WO2005110484A3 (en) 2006-08-24
WO2005110484A2 (en) 2005-11-24
CA2566190A1 (en) 2005-11-24
CN101287496A (zh) 2008-10-15
US20050250756A1 (en) 2005-11-10
EP1747017A2 (de) 2007-01-31
DE602005005666D1 (de) 2008-05-08
EP1747017B1 (de) 2008-03-26
DE602005005666T2 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
DE602005009195D1 (de) Verwendung einer gezielten oxidativen therapeutischen formulierung bei der behandlung von verbrennungen
WO2005107728A3 (en) Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
EP1385525A4 (de) Gerichtete oxidative therapeutische formulierung
SG135190A1 (en) Use of targeted oxidative therapeutic formulation in treatment of viral diseases
ATE384524T1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE60238255D1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
BR9709427A (pt) Oxa ácidos e compostos relacionados para tratamento de condições da pele
BR0212864A (pt) Derivados de 1,6-naftiridina como antidiabéticos
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2002078623A3 (en) Uses of targeted oxidative therapeutic formulation in arteriosclerosis
DE69815750D1 (de) Verfahren zur Herstellung von Ascorbinsäurederivaten
DE60135108D1 (de) Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
DE60220525D1 (de) Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
ATE390150T1 (de) Verwendungen einer targetierten therapeutischen formulierung fur die behandlung von altersbedingter makuladegeneration
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
WO2005110483A3 (en) Use of targeted oxidative therapeutic formulation in bone regeneration
DE69706142T2 (de) Benzofuran-acrylsaure-derivate und ihre anwendung als modulatoren der rxrs oder rars rezeptoren
BRPI0413682A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
ATE322244T1 (de) Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen
ATE178207T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen
ATE332697T1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
DE60222465D1 (de) Pyrazolopyridin-derivate als antiherpesmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties